|

Carfilzomib Clinical Trials

23 actively recruiting trials across 13 locations

Also known as: CFZ, Carfilnat, Kyprolis, Kyprolis®, PR 171 +1 more

Pipeline

Phase 1: 5Phase 2: 5Phase 3: 6Phase 4: 1Phase 1/2: 5

Top Sponsors

  • Roswell Park Cancer Institute2
  • Pfizer2
  • Hackensack Meridian Health2
  • AbbVie2
  • University of Chicago1

Indications

  • Cancer23
  • Multiple Myeloma15
  • Refractory Multiple Myeloma4
  • Recurrent Multiple Myeloma2
  • Relapsed Multiple Myeloma2

Other4 trials

Home Treatment With Carfilzomib in Patients With Multiple Myeloma
Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to Lenalidomide
Phase 1/2
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Phase 2
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Phase 4

Birmingham, Alabama3 trials

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

University of Alabama At Birmingham Hospital

Phase 1/2
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

University of Alabama at Birmingham

Phase 3
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

University of Alabama at Birmingham - Main /ID# 261434

Phase 3

Gilbert, Arizona3 trials

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Research Site

Phase 3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Banner MD Anderson Cancer Center

Phase 3
Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Miami, Florida2 trials

A Study of Daratumumab

University of Miami Sylvester Cancer Center

Phase 3
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

University of Miami

Phase 2

Buffalo, New York2 trials

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Roswell Park Cancer Institute

Phase 2
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Roswell Park Comprehensive Cancer Center

Phase 1

Mobile, Alabama1 trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Infirmary Cancer Care

Phase 3

Little Rock, Arkansas1 trial

A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

University of Arkansas for Medical Sciences

Phase 1

Duarte, California1 trial

Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

City of Hope Medical Center

Phase 1

La Jolla, California1 trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Denver, Colorado1 trial

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Colorado Blood Cancer Institute /ID# 273129

Phase 1/2

Washington D.C., District of Columbia1 trial

Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma

Lombardi Comprehensive Cancer Center

Phase 1/2

Chicago, Illinois1 trial

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

University of Chicago Medicine Comprehensive Cancer Center

Phase 2

Boston, Massachusetts1 trial

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Massachusetts General Hospital

Phase 2

Hackensack, New Jersey1 trial

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Hackensack Meridian Health - John Theurer Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.